Regional Chemotherapy for Cancer

Stehlin, John S.; Clark, R. Lee; White, Edgar C.; Smith, J. L.; Griffin, A. Clark; Jesse, Richard H.; Healey, John E.

doi:10.1097/00000658-196004000-00024

Cited by 89 publications

(13 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Approximately 25% of melanoma patients with locoregional metastases are nonresponsive to new molecular target therapy and immunotherapy 1 . For these patients, regional chemotherapy with alkylating agents could be an option on the basis of the results of several published reports for the lower extremity 2 , 3 and pelvis 4 – 9 . Being highly reactive molecules, the alkylating agents induce cell death by binding to DNA 10 .…”

Section: Introductionmentioning

confidence: 99%

MGMT methylation correlates with melphalan pelvic perfusion survival in stage III melanoma patients: a pilot study

et al. 2017

View full text Add to dashboard Cite

Approximately 25% of melanoma patients with locoregional metastases are nonresponsive to new molecular target therapy and immunotherapy. When metastases are located in the pelvis, melphalan hypoxic perfusion can be an optional treatment. Because methylation of MGMT promoter increases the efficacy of alkylating agents, studies on melanoma outcome of patients treated with melphalan regional chemotherapy should consider this epigenetic change. This study aims to evaluate whether the survival of stage III melanoma patients treated with melphalan regional chemotherapy may be correlated with MGMT methylation status. The metastatic tissues of 27 stage III melanoma patients with locoregional metastases located in the pelvis subjected to melphalan hypoxic pelvic perfusion were examined. The methylation status of the MGMT promoter was investigated by MS-MLPA probes analysis and the presence of the BRAF V600E mutation was analyzed by CAST-PCR. The median survival times were estimated using the Kaplan–Meier curves and were stratified according to the clinicopathological characteristics of patients and lesions. The overall median survival time was 17 months. The 1-year, 3-year, and 5-year survival rates were 66.7, 18.5, and 7.4%, respectively. Disease stage, burden, and percentage of MGMT methylation significantly affected survival. We estimated an MGMT promoter methylation cut-off of at least 14%, which was significantly associated with a longer survival after melphalan regional chemotherapy. Our data suggest that MGMT promoter methylation could be an important factor in determining which melanoma patients should receive melphalan regional chemotherapy, but its prognostic significance in the routine clinical setting needs to be clarified in a larger study.

show abstract

Section: Introductionmentioning

confidence: 99%

MGMT methylation correlates with melphalan pelvic perfusion survival in stage III melanoma patients: a pilot study

et al. 2017

View full text Add to dashboard Cite

show abstract

“…A No. 8 French polyethylene catheter was inserted in the isolated part of the left atrium through a pursestring opening in the left auricle (Fig. 1).…”

Section: Methodsmentioning

confidence: 99%

Mechlorethamine Perfusion of the Isolated Canine Lung

Baxter¹,

Goswitz²,

Pratt³

et al. 1962

Arch Surg

View full text Add to dashboard Cite

“…Using this technique, obviously feasible for only certain tumours, it proved possible to administer large doses of cytotoxic agents to the tumour area without producing serious side effects. Many reports appeared using this method of regional perfusion, (Creech et al, 1959;Krementz et al, , 1960Reemtsma et al, 1959;Austen et al, 1959;Hickey et al, 1959;Knock, 1959; Sullivan, Mliller and Sikes, 1959;Woodhall et at., 1959;Pierpont andBlades, 1960: Shingleton et al, 1959;Cooling, Garai and Staunton, 1962;Stehlin et al, 1960).…”

Section: Previous Literaturementioning

confidence: 99%